Author(s):
Payal N. Vaja, Harsh H. Madiya, Siddhi K. Upadhyay, Dilip R. Ghusar, Vivek P. Solanki, Chetan H. Borkhataria
Email(s):
payalvaja55@gmail.com
DOI:
10.52711/2231-5713.2025.00051 
Address:
Payal N. Vaja1, Harsh H. Madiya2, Siddhi K. Upadhyay3, Dilip R. Ghusar4, Vivek P. Solanki5, Chetan H. Borkhataria6
1Assistant Professor, School of Pharmacy, Dr. Subhash University, Junagadh -362001, Gujarat, India.
2,3,4,5Research Scholar, School of Pharmacy, Dr. Subhash University, Junagadh- 362001, Gujarat, India.
6Assistant Professor, Department of Pharmaceutics, B. K. Mody Government Pharmacy College, Rajkot-360003, Gujarat, India.
*Corresponding Author
Published In:
Volume - 15,
Issue - 4,
Year - 2025
ABSTRACT:
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that currently affects an estimated 55 million people worldwide, with projections indicating a rise to 139 million by 2050 due to an aging population. It is primarily characterized by the accumulation of amyloid-beta plaques and the spread of tau protein aggregates, leading to neuronal loss and cognitive decline. AD ranks as the sixth leading cause of death in the United States, yet existing treatments provide only limited symptomatic relief. Current pharmacological medications, tallying cholinesterase inhibitors and NMDA receptor foes, offer humble cognitive benefits but drop level to halt sickness progression. Recent developments in immunotherapy, especially monoclonal antibodies that target amyloid-beta, have demonstrated promise in reducing the buildup of plaque. However, these medicines go up against challenges, such as immune-related side impacts and confined practicality in advanced disease stages. Acetylcholinesterase inhibitors, which update cholinergic transmission, have been broadly utilized, but their ampleness remains restricted to side impact management. In order to provide more thorough treatment plans, examiners are directly looking into combination drugs, gene-based trade, and innovative disease-modifying techniques in light of these obstacles. This review provides an in-depth analysis of historical and emerging therapeutic strategies for AD, highlighting ongoing clinical research and innovative treatment developments. Additionally, it examines factors contributing to the increasing prevalence of AD, including genetic predisposition, environmental influences, and lifestyle factors. Understanding these elements is crucial in designing more effective interventions that go beyond symptomatic management and target the disease’s underlying mechanisms. This study intends to add to the expanding corpus of research aiming to enhance patient outcomes and decrease the progression of AD by addressing present issues and assessing potential future approaches in therapy
Cite this article:
Payal N. Vaja, Harsh H. Madiya, Siddhi K. Upadhyay, Dilip R. Ghusar, Vivek P. Solanki, Chetan H. Borkhataria. Innovative Approach: The Role of Acetylcholinesterase Immunotherapy in Alzheimer’s Treatment. Asian Journal of Pharmacy and Technology. 2025; 15(4):346-6. doi: 10.52711/2231-5713.2025.00051
Cite(Electronic):
Payal N. Vaja, Harsh H. Madiya, Siddhi K. Upadhyay, Dilip R. Ghusar, Vivek P. Solanki, Chetan H. Borkhataria. Innovative Approach: The Role of Acetylcholinesterase Immunotherapy in Alzheimer’s Treatment. Asian Journal of Pharmacy and Technology. 2025; 15(4):346-6. doi: 10.52711/2231-5713.2025.00051 Available on: https://ajptonline.com/AbstractView.aspx?PID=2025-15-4-4
REFERENCES:
1. Mota IF, de Lima LS, Santana BD, et. al. Alzheimer’s disease: innovative therapeutic approaches based on peptides and nanoparticles. The Neuroscientist. 2023 Feb; 29(1): 78-96.
2. AlzheimerEurope.Dementia in Europe Year book2019: estimating the prevalence of dementia in Europe. 2020. (Accessed Jan 24, 2021).
3. AbdelnourC, Agosta F, BozzaliM, et.al. Perspectivesand challengesin patientstratification in Alzheimer’s disease. Alzheimer's Research and Therapy. 2022 Aug 13; 14(1): 112.
4. Kuca K, Soukup O, Maresova P, et. al. Current approaches against Alzheimer's disease in clinical trials. Journal of the Brazilian Chemical Society. 2016 Apr; 27(4): 641-9.
5. Evans DA, Funkenstein HH, Albert MS, et. al. Prevalence of Alzheimer's disease in a community population of older persons: higher than previously reported. Jama. 1989 Nov 10; 262(18): 2551-6.
6. Pal T, Das M. Review of Alzheimer’s Disease’s Animal Model with its Pathophysiology and Drug Discovery.
7. Jadhav RP, Kengar MD, Narule OV, Koli VW, Kumbhar SB. A review on Alzheimer's Disease (AD) and its herbal treatment of Alzheimer's Disease. Asian Journal of Research in Pharmaceutical Science. 2019; 9(2): 112-22.
8. PattersonC.World Alzheimerreport 2018. London: Alzheimer’s Disease International; 2018.
9. PradoCE, WattS, Tree by MS, Crowe SF. Performance on neuro psychological assessment and progression to dementia: A meta-analysis. Psychology and Aging. 2019 Nov; 34(7): 954.
10. Naidu C, Kumar D, Maheswari N, Sivagami M. Prediction of Alzheimer's Disease using Brain Images. Research Journal of Pharmacy and Technology. 2018; 11(12): 5365-8.
11. Kumar DR, Shankar MS, Reddy PP, Kumar BR, Sumalatha N. A Review on Alzheimer's Disease. Research journal of Pharmacology and Pharmacodynamics. 2014; 6(1): 59.
12. Patel CK, Panigrahi B, Badmanaban R, Patel CN. Biochemical Origins of Alzheimer's Disease with Treatment Techniques. Research Journal of Pharmacology and Pharmacodynamics. 2010; 2(1): 33-8.
13. ZhangJ, ZhangY, WangJ, XiaY, ZhangJ, ChenL. Recent advances in Alzheimer’sdisease: Mechanisms, clinical trials and new drug development strategies. Signal Transduction and Targeted Therapy. 2024 Aug 23;9(1):211.
14. Thakur AK, Kamboj P, Goswami K, Ahuja KJ. Pathophysiology and management of Alzheimer’s disease: An overview. J Anal Pharm Research. 2018 Apr; 9(2): 226-35.
15. Breijyeh Z, Karaman R. Comprehensive Review on Alzheimer's Disease: Causes and Treatment. Molecules. 2020 Dec 8; 25(24): 5789.
16. Cenini G, Lloret A, Cascella R. Oxidative stress in neurodegenerative diseases: from a mitochondrial point of view. Oxidative Medicine and Cellular Longevity. 2019; 2019(1): 2105607.
17. MohamedT, ShakeriA, RaoPP. Amyloidcascade in Alzheimer's disease: Recent advances in medicinal chemistry. European Journal of Medicinal Chemistry. 2016 May 4; 113:258-72.
18. WeekleyCM, HeC. Developing drugs target in transition metal homeostasis. Current Opinion in Chemical Biology. 2017 Apr 1; 37: 26-32.
19. Prakash A, Dhaliwal GK, Kumar P, et. al. Brain bio-metals and Alzheimer's disease–boon or bane. International Journal of Neuroscience. 2017 Feb 1; 127(2): 99-108.
20. Chase TN, Farlow MR, Clarence-Smith K. Donepezil plus solifenacin (CPC-201) treatment for Alzheimer's disease. Neurotherapeutics. 2017 Apr 1; 14(2): 405-16.
21. Cho Y, Bae H G, Okun E, et. al. Physiologyand pharmacologyof amyloid precursor protein. Pharmacol Therapy 2022 Jul; 235: 108122.
22. MaC, HongF, YangS. Amyloidosis in Alzheimer's Disease: Pathogeny, Etiology, and Related Therapeutic Directions. Molecules. 2022 Feb 11; 27(4): 1210.
23. P, P. Immun other apyasa Cancer Treatment Option in the Future. Health Science Journal. 2023, 17, 1−3.
24. Coley, W.B. Thetreatment of malignant tumours by repeated in oculations of erysipelas. With a report of ten original cases. 1893. The American Journal of the Medical Science. 1893; 105: 487−510.
25. Szyszka-Barth, K.; Ramlau, K.; Gozdzik-Spychalska, J.; et. al. Actual status of therapeutic vaccination in non-small cell lung cancer. Contemp Oncol (Pozn). 2014; 18: 77−84.
26. Sen A, Kumar K, Khan S, Pathak P, Singh A. Current Therapy in Cancer: Advances, Challenges, and Future Directions. Asian Journal of Nursing Education and Research. 2024; 14(1): 77-84.
27. Kumar A, Singh K, Kumar K, Kumar S, Singh A. Immunotherapy in cancer treatment: Harnessing the power of the immune system. Research Journal of Pharmaceutical Dosage Forms and Technology. 2024 Feb 22; 16(1): 107-12.
28. Nichols, E. Estimation of the global prevalence of dementiain 2019 and for ecasted prevalence in 2050: ananalys is for the Global Burden of Disease Study 2019. Lancet Public Health. 2022; 7: 105−125.
29. Anawal L, Chandrashekar VM, Shalavadi M, Teli S, Madalageri M, Sadashivanavar V, Patil V, Kumbar S, Horatti P. Neuroprotective Activity of Polyherbal Formulation on Colchicine Induced Alzheimer’s Disease in Rat Model. Asian Journal of Pharmacy and Technology. 2024 Sep 1; 14(3).
30. IslamMR, RabbiMA, HossainT, SultanaS, UddinS. Mechanistic Approach to Immunity and Immunotherapy of Alzheimer’s Disease: A Review. ACS Chemical Neuroscience. 2024 Sep 2.
31. Gilman, S.; Koller, M.; Black, R. S.; et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial. Neurology. 2005; 64:1553−62.
32. Winblad, B.; Andreasen, N.; Minthon, L.; et al. Safety, tolerability, and antibodyresponse of active Aβ immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo- controlled, first-in-human study. Lancet Neurology. 2012; 11: 597−604.
33. Pasquier, F., Sadowsky, C., Holstein, A., et. al. Two Phase2 Multiple Ascending−DoseStudies of Vanutide Cridificar (ACC-001) and QS-21 Adjuvant in Mild-to-Moderate Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2016; 51: 1131−43.
34. Davtyan, H.; Ghochikyan, A.; Petrushina, I.; et al. Immunogenicity, Efficacy, Safety, and Mechanism of Action of Epitope Vaccine (Lu AF20513) for Alzheimer’s Disease: Prelude to a Clinical Trial. J. Neurosci. 2013; 33: 4923−34.
35. Yu, H.J.; Dickson, S.P.; Wang, P.N.; Chiu, M.J.; Huang, C.C.; Chang, C.C.; Liu, H.; et al. Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer’s disease: a randomised, double-blind, placebo-controlled, phase 2a study. eBioMedicine. 2023: 94.
36. Plascencia-Villa, G.; Perry, G. Chapter 16- Lessons from antiamyloid-β immunotherapies in Alzheimer’s disease. In: Espay, A. J., editor. Handbook of Clinical Neurology, 2013; 193: 267− 91.
37. Mo, J.-J.; Li, J.; Yang, Z.; et. al. Efficacy and safety of anti-amyloid-β immunotherapy for Alzheimer’s disease: a systematic review and network meta-analysis. Annals of Clinical and Translational Neurology. 2017; 4: 931−42.
38. Lacosta, A.-M.; Pascual-Lucas, M.; Pesini, P.; et al. Safety, tolerability and immunogenicity ofanactiveanti-Aβ40vaccine (ABvac40) in patients with Alzheimer’s disease: arandomised, double-blind, placebo controlled, phase I trial. Alzheimer Research Therapy. 2018; 10: 12.
39. Nimmo, J.T.; Kelly.; Verma, A.; et. al. Amyloid-β and α-Synuclein Immunotherapy: From Experimental Studies to Clinical Trials. Front Neuroscience. 2021; 15: 15.
40. Petrushina, I.; Hovakimyan, A.; Harahap-Carrillo, I.S.; et al. Characterization and preclinical evaluation of the cGMP grade DNA based vaccine, AV 1959D toenter the first-in-human clinical trials. Neurobiology of Disease. 2020; 139: 104823.
41. Liu, D.; Lu, S.; Zhang, L.; etal. Yeast Based Aβ1−15 Vaccine Elicits Strong Immunogenicity and Attenuates Neuropathology and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice. Vaccines. 2020; 8: 351.
42. Plascencia-Villa, G.; Perry, G. Chapter One- Status and future directions of clinical trials in Alzheimer’s disease. In: Söderbom, G.; Esterline, R.; Oscarsson, J.; Mattson, M. P. International Review of Neurobiology. 2020; 154: 3−50.
43. Sevigny, J.; Chiao, P.; Bussiere, T.; et al. The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. 2016; 537: 50−6.
44. Sevigny, J.; Chiao, P.; Bussière, T.; Weinreb, P.H.; Williams, L.; Maier, M.; Dunstan, R.; Salloway, S.; Chen, T.; Ling, Y.; et al. The antibody aducanumab reduces A plaques in Alzheimer’s disease. Nature. 2016; 537: 50–56.
45. Salloway, S.; Sperling, R.; Fox, N.C.; et al. Two Phase 3Trials of Bapineuzumabin Mild-to- Moderate Alzheimer’s Disease. New England Journal of Medicine. 2014; 370: 322−33.
46. Ostrowitzki, S.; Bittner, T.; Sink, K. M.; et al. Evaluating the Safety and Efficacy of Crenezumab vs Placebo in Adults with Early Alzheimer Disease: Two Phase 3 Randomized Placebo-Controlled Trials. JAMA Neurology. 2022; 79: 1113−21.
47. Demattos, R. B.; Lu, J.; Tang, Y.; et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer’s disease mice. Neuron. 2012; 76: 908−20.
48. Guo, X.; Yan, L.; Zhang, D.; Zhao, Y. Passiveimmun other apy for Alzheimer’sdisease.Ageing Research Reviews. 2024; 94: 102192.
49. Englund, H.; Sehlin, D.; Johansson, A.-S.; et al. Sensitive ELISA detection of amyloid-β protofibrils in biological samples. Journal of Neurochemistry. 2007; 103: 334−45.
50. Honig, L. S.; Vellas, B.; Woodward, M.; et al. Trial of Solanezumab for Mild Dementia Due to Alzheimer’s Disease. N Engl J. Med. 2018; 378: 321−30.
51. Bright, J.; Hussain, S.; Dang, V.; etal. Human secreted tau increases amyloid-betaproduction. Neurobiology of Aging. 2015; 36: 693−709.
52. Florian, H.; Wang, D.; Arnold, S. E.; et al. Tilavonemab in early Alzheimer’s disease: results from a phase 2, randomized, double-blind study. Brain. 2023; 146: 2275−84.
53. Jicha, G.A.; BowserR.; KazamI.G.; DaviesP.Alz-50andMC1, a new monoclonal antibody raised to paired helical filaments, recognize conformational epitopes on recombinant tau. Journal of Neuroscience Research. 1997; 48: 128−32.
54. Jann MW. Pharmacology and clinical efficacy of cholinesterase inhibitors. Am J Health Syst Pharm. 1998; 55 Suppl. 2: S22-5
55. Corey-Bloom J, Anand R, Veach J. Arandomized trial evaluating the efficacy and safety of ENA713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psycho-Pharm. 1998; 1: 55-65
56. Wengel SP, Roccaforte WH, Burke WJ. Donepezil improves symptoms of delirium in dementia: implications for future research. J Geriatr Psychiatry Neurol. 1998; 11(3): 159-61
57. Mega MS, Masterman DM, O'Connor SM, Barclay TR, Cummings JL. The spectrum of behavioural responses to cholinesterase inhibitor therapy in Alzheimer disease. Archives of Neurology. 1999 Nov 1; 56(11): 1388-93.
58. Cumming JL. Cholinesterase inhibitors: a new class of psycho-tropic compounds. Am J Psychiatry. 2000; 157 (1): 4-15
59. GiacobiniE, CuadraG.Secondandthirdgenerationcholinesteraseinhibitors: frompreclinical studies to clinical efficacy. In: BeckerR, GiacobiniE, SmithDL, editors. Alzheimer’sdisease: therapeutic strategies. Boston: Birkhauser. 1994: 155-71
60. Folstein MF, Folstein SE, McHugh PR. ‘Mini-mentalstate’: apracticalmethodforgradingthe cognitive state of patients for the clinician. Journal of Psychiatry Research. 1975; 12(3): 189- 98
61. MohsR, DoodyR, MorrisJ, etal. Donepezilpre serves activities of daily living in Alzheimer’s disease patients: results from a one-year placebo-controlled functional survival study. Neurology. 2000; 54 Suppl. 3: A415
62. Tiseo PJ, Perdomo CA, FriedhoffL T. Metabol is mandelimination of 14C-donepezilinhealthy volunteers: asingle-dosestudy. Br Journal of Clinical Pharmacology. 1998; 46Suppl.1: 19-24
63. Davies-Lepie SR. Tacrine may prolong the effect of succinyl choline. Anaesthesiology. 1994; 81 (2): 524
64. GrutzendlerJ, Morris JC. Cholinesterase inhibitors for Alzheimer’s disease. Drugs. 2001 Jan; 61: 41-52.
65. Takada Y, Yonezawa A, Kume T, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. Journal of Pharmacological Experimental Therapy. 2003 Aug; 306(2): 772-7
66. Emre M, Bernabei R, Blesa R, et al. Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease. CNS Neuroscience Therapy. 2010 Aug; 16(4): 246-53
67. SeltzerB.Galantamine-ER for the treatment of mild-to-moderate Alzheimer’sdisease.Clinical Interventions in Aging. 2010 Feb 2: 1-6.
68. Plosker GL, Gauthier S. Cerebrolysin: a review of its use in dementia. Drugs & Aging. 2009; 26(11): 893-915
69. Sharma VK. Current Therapeutic Strategies for Alzheimer's disease: A Lost Direction or A Hope Remains? Research Journal of Pharmacology and Pharmacodynamics. 2010; 2(3): 215-20.
70. Patel M. A Review on Importance of Artificial Intelligence in Alzheimer's Disease and it's Future Outcomes for Alzheimer's Disease. Research Journal of Pharmacology and Pharmacodynamics. 2022; 14(1): 13-22.
71. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer’s Disease. N Engl J Med. 2023; 388:9-21.
72. Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer’s Disease. JAMA. 2023; 330(1): 33-44.